NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Meirluc,

You are right. The first 38 patients did not do well. Only 5 or 6 of the “unknown” 38 patients had lived to 36 months.
That is 13.1% or 15.8% Survival at 3 years.

The next group of 144 (182-38) patients did much better.
38 or 39 of the 144 had lived to 36 months.
That is 26.4% or 27.1%.Survival at 3 years

And now it becomes interesting.
Seven patients were censored between 30 and 36 months on the OS curve March 2017 (censors 73-74-75-76-77-78 and 79 Sentiments curve).

https://investorshub.advfn.com/uimage/uploads/2018/10/22/gddzjCombined_charts_no_notes_revised_-lykiri.jpg

In the best case, all 7 patients had lived to 36 months. If so, we have a group of 51 (44 + 7) out of a total of 223 patients.(74 placebo and 149 treatment)
51/223 = 22.87% Survival at 3 years.

From the new data 2018 we know that the survival rate at 3 years = 28.2%. That is 93 patients (n=331).

From @rago_carlo more to come. Seems like it's ahead of Optune pic.twitter.com/smkMT95TuK

— Michael Bigger (@biggercapital) November 17, 2018

We have a final group of 108 patients who had their surgery between September 2014 and August 2015. We all know that this is a group of sicker patients. The Germans halved their white blood cell count criteria in the DCVax trial. 83 patients are treatment and 25 are placebo.(83 +25=108)(IMO)

At least 42 patients (93-51) of this sicker group of patients (n=108) had lived to 36 months.
42/108= 38.89 % survival rate at 3 years.

If all these 42 patients are treatment, the Survival rate at 3 years = 50.6%.(42 of a group of 83 dcvax-l patients)

I repeat, if all these 42 patients are treatment, the Survival rate at 3 years = 50.6%.(of this final group of treatment patients)

I end with this famous quote:

The data are what they are.( Pyrrhonian Monday November 12,2018)

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144840140
All my opinion.